LI Gui-ling - Tongji Medical College, Huazhong University of Science and Technology

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 26 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Supplementary Figure S1 from Cadonilimab Combined with Chemotherapy with or Without Bevacizumab As First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study

Hanmei Lou,Hongbing Cai,Xin Huang,Guiling Li,Li Wang, Fei Liu,Wenjing Qin,Ting Liu,Wei Liu,Zhongmin Maxwell Wang,Baiyong Li,Yu Xia,Jing Wang

crossref（2024）

引用0浏览0引用

The Efficacy and Safety of RC88 in Patients with Ovarian Cancer, Non-Squamous-non-small-cell Lung-Carcinoma and Cervical Cancer: Results from a First-in-human Phase 1/2 Study

Yutao Liu,Guiling Li,Runxiang Yang, Yu Huang,Suxia Luo,Qi Dang,Qingshui Li,Dingzhi Huang,Yi Huang,Dihong Tang,Xiubao Ren,Youzhong Zhang,Yuguang Zhao,Baorui Liu,Jin Zhou, Yanjie Wang, Heping Liu, Beisong Liu,Jianmin Fang,Yuankai Shi

JOURNAL OF CLINICAL ONCOLOGY（2024）

引用0浏览0引用

Efficacy and Safety of 9 MW2821, an Antibody-Drug Conjugate Targeting Nectin-4 Monotherapy, in Patients with Recurrent or Metastatic Cervical Cancer: A Multicenter, Open-Label, Phase I/II Study

Huijuan Yang,Jian Zhang,Rujiao Liu,Shuiping Gao,Hanmei Lou,Guiling Li,Hualei Bu, Rong Li, Shanbing Wang, Shujing Shen, Mingjun Zhang, Peipei Wang, Zhe Feng, Nan Chu

Gynecologic Oncology (2024)

引用0浏览0引用

Supplementary Figure S2 from Cadonilimab Combined with Chemotherapy with or Without Bevacizumab As First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study

Hanmei Lou,Hongbing Cai,Xin Huang,Guiling Li,Li Wang, Fei Liu,Wenjing Qin,Ting Liu,Wei Liu,Zhongmin Maxwell Wang,Baiyong Li,Yu Xia,Jing Wang

crossref（2024）

引用0浏览0引用

A Phase 1/2 Study of the TORC1/2 Inhibitor Onatasertib Combined with Toripalimab in Patients with Advanced Solid Tumors: Cervical Cancer Cohort

Li Yuan,Pei Shu,Xiaoyu Li,Guiling Li,Keqiang Zhang, Lin Lai, Jinsheng Hong,Chu-Ying Huang,Yongsheng Wang, Hui Xie,Li Zheng,Qi Zhou

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

Biomarker-driven Targeted Therapy in Patients with Recurrent Platinum-Resistant Epithelial Ovarian Cancer (BRIGHT): Protocol for an Open-Label, Multicenter, Umbrella Study

Yu Xu, Fan Xiong,Huayi Li,Hong Zheng,Jie Jiang,Qingshui Li,Guiling Li,Weidong Zhao,Rong Li,Jundong Li,Rong Xie,Ruifang An,Huifeng Zhang,Qinglei Gao

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER（2024）

引用0浏览0WOS引用

Evaluation of the Effectiveness and Safety of Disitamab Vedotin in HER2-expressing 2L Recurrent or Metastatic Cervical Cancer (r/mcc): Interim Results of RC48-C018

Guangwen Yuan,Guiling Li,Qingshui Li,Youzhong Zhang,Ruifang An,Jinwei Miao,Keqiang Zhang,Hongying Yang,Yi Huang,Ruixia Guo, Li Sun,An Lin,Junying Tang,Xiumin Li,Jianming Ying,Yun Ling, Yanan Wang, Haiwen Zhou,Jianmin Fang,Lingying Wu

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

Supplementary Table S3 from Cadonilimab Combined with Chemotherapy with or Without Bevacizumab As First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study

Hanmei Lou,Hongbing Cai,Xin Huang,Guiling Li,Li Wang,Fei Liu,Wenjing Qin,Ting Liu,Wei Liu,Zhongmin Maxwell Wang,Baiyong Li,Yu Xia,Jing Wang

crossref（2024）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn